#JPM23: Is 2023 go­ing to be a bet­ter year for biotech deal­mak­ing?

Last year of­fered a dis­ap­point­ing stretch for biotech, with few­er deals than ex­pect­ed and lots more head­winds. End­points News Ed­i­tor-in-Chief John Car­roll sat down with some of the in­dus­try’s top deal­mak­ers to ex­plore what hap­pened, and what’s ahead in 2023. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

John Car­roll:

I’d say this is one of the most im­por­tant con­ver­sa­tions that’s go­ing on right now. Par­tic­u­lar­ly, of course, at JP Mor­gan, be­cause so many peo­ple have come here, specif­i­cal­ly to get in­volved in a deal, to see what they can do about a deal, to see what the deal po­ten­tial is, where things are head­ed, what the trends are. Every­thing that we’re go­ing to be cov­er­ing here in the next hour.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER